NASDAQ:RCM - R1 RCM Stock Price, Forecast & News

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

R1 RCM Inc (NASDAQ:RCM) issued its earnings results on Tuesday, November, 5th. The healthcare provider reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by $0.08. The healthcare provider had revenue of $301.20 million for the quarter, compared to analyst estimates of $302.85 million. The business's quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.17) EPS. View R1 RCM's Earnings History.

R1 RCM is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for R1 RCM.

R1 RCM will be holding an earnings conference call on Thursday, February 20th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 brokerages have issued twelve-month price targets for R1 RCM's stock. Their forecasts range from $14.00 to $17.00. On average, they anticipate R1 RCM's share price to reach $15.25 in the next twelve months. This suggests a possible upside of 15.0% from the stock's current price. View Analyst Price Targets for R1 RCM.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for R1 RCM.

News articles about RCM stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. R1 RCM earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the healthcare provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for R1 RCM.

R1 RCM saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 7,780,000 shares, an increase of 17.3% from the December 31st total of 6,630,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 6.7 days. Approximately 8.0% of the shares of the stock are short sold. View R1 RCM's Current Options Chain.

Some companies that are related to R1 RCM include BioScrip (BIOS), Amedisys (AMED), AMN Healthcare Services (AMN), Chemed (CHE), CorVel (CRVL), Cross Country Healthcare (CCRN), Davita (DVA), Interpace Diagnostics Group (IDXG), Laboratory Corp. of America (LH), LHC Group (LHCG), MEDNAX (MD), Quest Diagnostics (DGX), The Providence Service (PRSC) and Tivity Health (TVTY).

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include Alibaba Group (BABA), NVIDIA (NVDA), Baozun (BZUN), Marvell Technology Group (MRVL), JD.Com (JD), Model N (MODN), Fortinet (FTNT), NMI (NMIH), Perficient (PRFT) and SeaChange International (SEAC).

R1 RCM's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (2.27%), State Street Corp (2.00%), Bank of New York Mellon Corp (1.92%), Royce & Associates LP (1.15%), Eaton Vance Management (1.14%) and Sectoral Asset Management Inc (1.03%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli and Charles J Ditkoff. View Institutional Ownership Trends for R1 RCM.

RCM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Penn Capital Management Co. Inc., Falcon Point Capital LLC, Point72 Asset Management L.P., Castleark Management LLC, PNC Financial Services Group Inc., Prudential Financial Inc. and Russell Investments Group Ltd.. View Insider Buying and Selling for R1 RCM.

RCM stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Mckinley Capital Management LLC Delaware, Eaton Vance Management, Eagle Asset Management Inc., Tealwood Asset Management Inc., Parkman Healthcare Partners LLC, Bank of Montreal Can and Sectoral Asset Management Inc. View Insider Buying and Selling for R1 RCM.

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RCM stock can currently be purchased for approximately $13.26.